Working together to beat cancer

Cancer Research UK and Start Codon
Start Codon has joined Cancer Research UK’s Entrepreneurial Programmes Initiative, which aims to develop and nurture an entrepreneurial culture amongst cancer researchers in the UK.

Cancer Research UK’s ambition is for 3 out of 4 patients diagnosed with cancer to survive the disease by 2034. To achieve this, they are supporting researchers to accelerate the translation of ideas and discoveries into products that will improve the lives of cancer patients.

Cancer Research UK’s Entrepreneurial Programme will show you how to build a business, connect you to a network of like-minded people and help you find the right advice and support, when you need it.

Read about the programme

Our role

As part of the Entrepreneurial Programmes Initiative, the Start Codon training scheme aims to educate a multi-disciplinary oncology research community about entrepreneurship, company formation, operations and fundraising, with the goal of supporting the development of viable start-up businesses that will address unmet medical needs. The scheme is open nationwide and based in Cambridge, UK, cluster.


The training scheme

The scheme is designed primarily to help PhD students, postdocs, and junior group leaders; however, all researchers interested in fighting cancer are encouraged to get involved, regardless of their career stage or discipline.

As part of the scheme, researchers will be:

  • invited to attend educational workshops on a wide range of topics such as entrepreneurship, company formation, operations, team building, market research, and fundraising
  • exposed to monthly networking events to connect them with rising star mentors and serial entrepreneurs
  • given the opportunity to interact with scientists from vastly different disciplines to co-develop ground-breaking new cancer therapeutic diagnostic and preventative solutions
  • regularly informed about the funding available to support their work, including both grants and other non-dilutive funding as well as angel investment and venture capital

Together, we can stop cancer in its tracks

Join us Download press release